Dubai Lab Tests Top Services
Search Box (All Fields Optional)
Showing 1041 – 1060 out of 1141
Page 53 out of 58
| Thumbnails | Products | Price | Quantity | Action | |
|---|---|---|---|---|---|
|
|
 |
د.إ5,500.00
|
|
||
|
|
 |
Oncomine Acute Myeloid Leukemia (AML) Panel – Targeted NGS Solution for AML Research
The Oncomine Acute Myeloid Leukaemia (AML) Panel is a targeted next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of AML. It enables simultaneous detection of key mutations, gene fusions, and copy number variations across clinically relevant genes associated with AML. |
د.إ5,500.00
|
|
|
|
|
|
د.إ5,500.00
|
|
||
|
|
|
د.إ5,500.00
|
|
||
|
|
|
Oncomine Comprehensive myeloid/ Leukemia Panel (DNA + RNA fusions)
The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes. |
د.إ5,500.00
|
|
|
|
|
|
د.إ5,500.00
|
|
||
|
|
|
د.إ5,500.00
|
|
||
|
|
|
د.إ5,500.00
|
|
||
|
|
|
د.إ4,100.00
|
|
||
|
|
 |
Oncomine Myeloproliferative Neoplasm (MPN) Panel – Accurate NGS Testing for MPN Mutations
The Oncomine Myeloproliferative Neoplasm (MPN) Panel is a targeted next-generation sequencing (NGS) assay designed for the comprehensive detection of key driver mutations in myeloproliferative neoplasms. It enables the simultaneous analysis of JAK2, CALR, and MPL genes, which are critical for MPN diagnosis and classification. The panel offers high sensitivity, detecting low-frequency variants with as little as 10 ng of input RNA or DNA, making it ideal for limited or degraded samples. |
د.إ5,500.00
|
|
|
|
|
|
د.إ5,500.00
|
|
||
|
|
|
د.إ5,500.00
|
|
||
|
|
 |
Jak 2 Exon 12-15 Mutation Analysis | Accurate Genetic Testing & Results
The Jak 2 Exon 12-15 Mutation Analysis is a specialized genetic test designed to detect mutations in exons 12-15 of the JAK2 gene, which are associated with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV) and other hematologic disorders. This test offers high sensitivity and specificity, enabling early and accurate diagnosis, which is crucial for targeted treatment decisions and disease monitoring. Unlike standard JAK2 V617F mutation tests, this analysis identifies rare but clinically significant mutations, providing comprehensive genetic profiling for patients with suspected MPNs. Its advanced molecular technology ensures reliable results, supporting personalized therapeutic strategies and improving patient outcomes. |
د.إ2,720.00
|
|
|
|
|
|
د.إ3,200.00
|
|
||
|
|
|
د.إ2,800.00
|
|
||
|
|
|
د.إ2,800.00
|
|
||
|
|
|
د.إ4,500.00
|
|
||
|
|
|
د.إ5,500.00
|
|
||
|
|
|
د.إ5,500.00
|
|
||
|
|
 |
Hereditary Cancer Gene Panel – 57 ACMG Genes for Genetic Risk Screening
The **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**. |
د.إ4,000.00
|
|